Core Viewpoint - Treace Medical Concepts, Inc. is facing a class action securities lawsuit due to alleged securities fraud impacting investors between May 8, 2023, and May 7, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Treace Medical's primary product, the 3D bunion correction system "Lapiplasty," was negatively affected by competition, leading to a decline in revenue [2]. - It is alleged that the company needed to expedite plans for an alternative product to osteotomy due to this decline [2]. - Defendants are accused of making materially misleading statements regarding the company's business and prospects [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until June 10, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Legal Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the U.S. [4]. - The firm has over 70 employees dedicated to serving clients in complex securities litigation [4].

Treace Medical Concepts (TMCI) closed the last trading session at $7.20, gaining 6.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $10.16 indicates a 41.1% upside potential.The mean estimate comprises seven short-term price targets with a standard deviation of $2.16. While the lowest estimate of $8 indicates an 11.1% increase from the current price level, the most optimistic ana ...

Core Viewpoint - A class action lawsuit has been filed against Treace Medical Concepts, Inc for alleged securities fraud and unlawful business practices [2][3]. Group 1: Lawsuit Details - The lawsuit involves Treace Medical and certain officers and/or directors accused of engaging in securities fraud [2]. - Investors who purchased Treace Medical securities during the Class Period have until June 10, 2025, to request to be appointed as Lead Plaintiff [3]. Group 2: Financial Performance - On May 7, 2024, Treace Medical lowered its full-year 2024 revenue guidance from a range of $220 million to $225 million down to $201 million to $211 million [3]. - The company cited competition from minimally invasive osteotomy and Lapiplasty "knockoffs" as headwinds affecting Lapiplasty growth [3]. Group 3: Stock Market Reaction - Following the revenue guidance cut, Treace Medical's stock price fell by $6.95, or nearly 63%, closing at $4.17 per share on May 8, 2024, with unusually high trading volume [4].

NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Treace Medical Concepts, Inc. (NASDAQ: TMCI). Shareholders who purchased shares of TMCI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/treace-medical-concepts-inc-loss-submission-form-2/?id=147738&from=3 ...

NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, has filed a securities class action lawsuit in the United States District Court for the Middle District of Florida against Treace Medical Concepts, Inc. (“Treace Medical” or the “Company”) (NASDAQ: TMCI), and certain of its former and current officers and/or directors (collectively, “Defendants”). The Class Action asserts claims under §§10(b) and 20(a ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Treace Medical Concepts, Inc. regarding a class action lawsuit due to alleged misleading statements and failure to disclose critical information affecting the company's stock value [1]. Group 1: Allegations and Impact - The complaint alleges that during the class period from May 8, 2023, to May 7, 2024, Treace Medical faced competition that negatively impacted the demand for its primary product, the 3D bunion correction system known as "Lapiplasty" [1]. - As a result of the competition, Treace Medical's revenue declined, prompting the company to accelerate plans for an alternative product to osteotomy [1]. - The defendants are accused of making materially misleading statements about the company's business operations and future prospects, lacking a reasonable basis [1]. Group 2: Class Action Details - Shareholders who purchased TMCI shares during the specified class period are encouraged to register for the class action, with a deadline set for June 10, 2025 [2]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [2]. - Participation in the case does not incur any cost or obligation for the shareholders [2]. Group 3: Law Firm's Mission - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit, fraud, and illegal business practices [3]. - The firm aims to ensure that companies adhere to responsible business practices and engage in good corporate citizenship [3]. - The firm seeks recovery for investors who suffered losses due to false or misleading statements that led to artificial inflation of the company's stock [3].

NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, has filed a securities class action lawsuit in the United States District Court for the Middle District of Florida against Treace Medical Concepts, Inc. (“Treace Medical” or the “Company”) (NASDAQ: TMCI), and certain of its former and current officers and/or directors (collectively, “Defendants”). The Class Action asserts claims under §§10(b) and 20(a ...

Core Viewpoint - A class action securities lawsuit has been filed against Treace Medical Concepts, Inc. due to alleged securities fraud impacting investors between May 8, 2023, and May 7, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Treace Medical's primary product, the 3D bunion correction system "Lapiplasty," faced decreased demand due to competition [2]. - As a result of this competition, Treace Medical's revenue declined, prompting the company to expedite plans for an alternative product to osteotomy [2]. - The defendants are accused of making materially misleading statements regarding the company's business operations and future prospects [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until June 10, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

分组1 - Treace Medical Concepts reported a quarterly loss of $0.25 per share, better than the Zacks Consensus Estimate of a loss of $0.31, and an improvement from a loss of $0.30 per share a year ago, representing an earnings surprise of 19.35% [1] - The company posted revenues of $52.57 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.05%, and an increase from year-ago revenues of $51.11 million [2] - Treace Medical Concepts has surpassed consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates four times during the same period [2] 分组2 - The stock has lost about 3.2% since the beginning of the year, while the S&P 500 has declined by 4.3% [3] - The current consensus EPS estimate for the coming quarter is -$0.27 on revenues of $49.66 million, and for the current fiscal year, it is -$0.86 on revenues of $227.44 million [7] - The Medical - Instruments industry, to which Treace Medical Concepts belongs, is currently in the top 28% of Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Financial Data and Key Metrics Changes - Revenue in Q1 2025 was $52.6 million, representing a 3% increase compared to Q1 2024, and adjusted for one less selling day, growth was 4.5% [4][9][17] - Gross margin was 79.7% in Q1 2025, down from 80.2% in Q1 2024 [18] - Net loss for Q1 2025 was $15.9 million or $0.25 per share, compared to a net loss of $18.7 million or $0.30 per share in Q1 2024 [18] - Adjusted EBITDA loss improved to $3.8 million in Q1 2025 from $8.3 million in Q1 2024, marking a 54% improvement [18][19] - Cash and cash equivalents were $76.1 million as of March 31, 2025, compared to $75.7 million as of December 31, 2024 [19] Business Line Data and Key Metrics Changes - The growth in revenue was primarily driven by an increase in bunion procedure kits sold compared to the prior year [17] - The company has established a strong customer base of over 3,100 surgeon users and treated over 130,000 patients since its inception [10] Market Data and Key Metrics Changes - The company expects to target virtually 100% of surgeon and patient preferences for bunion correction with five best-in-class systems starting in Q3 2025 [11] - The company anticipates substantial growth in Q4 2025, driven by the timing of patient deductibles and the full availability of new products [15] Company Strategy and Development Direction - The company aims to evolve from a single technology lapoplasty company to a comprehensive bunion solutions provider [10] - The upcoming commercialization of three new bunion correction systems is expected to enhance market penetration and address a broader range of surgeon preferences [11][12] - The company plans to launch several new sterile instruments and a next-generation lapoplasty platform later in the year [13][14] Management's Comments on Operating Environment and Future Outlook - Management reiterated revenue guidance for 2025, expecting revenue between $224 million and $230 million, representing a growth of 7% to 10% over 2024 [15][20] - The company is focused on achieving breakeven adjusted EBITDA for the full year 2025 and expects cash burn to decrease by approximately 50% compared to 2024 [21][62] Other Important Information - The company has limited tariff exposure, with most inventory manufactured in the U.S., and expects this to remain at immaterial levels in 2026 [21] Q&A Session Summary Question: How does the company feel about its positioning in the overall market today? - Management noted that competition remains, but the company believes lapoplasty is the superior option backed by clinical outcomes data [25][26] Question: Are there changes in how quickly new surgeon users are being trained? - Management reported strong interest and oversold attendance at training events, indicating excitement among surgeons [28] Question: What explains the expected sales for Q2 being below street estimates? - Management explained that elective procedures have been pushed out, but they expect these cases to be completed later in the year, benefiting from the expanded product portfolio [34][39] Question: How will the new products impact lapoplasty volumes? - Management indicated minimal cannibalization, as new products will primarily attract surgeons who prefer osteotomy procedures [40][44] Question: How might outpatient ASC reimbursement impact performance? - Management stated it is too early to quantify the impact but noted positive anecdotal feedback from surgeons regarding access to newer technologies [48][50] Question: What are the assumptions for the revenue guidance? - Management emphasized comfort with the midpoint of the revenue range, with potential upside from faster adoption of new products [56][58] Question: What are the drivers of positive leverage for EBITDA? - Management highlighted operational efficiencies and expense management as key drivers for improved profitability [59][62]